Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120831 | 0.81 | KMT2A (0.33) | APAF1TDP2NSD2HKDC1 | |
| SCHEMBL6129222 | 0.79 | APAF1 (0.35) | APAF1TDP2NSD2HKDC1 | |
| SCHEMBL23259904 | 0.76 | CHRM3 (0.34) | CHRM3 | |
| SCHEMBL23554968 | 0.73 | ALDH1A1 (0.33) | APAF1TDP2NSD2HKDC1 | |
| SCHEMBL6129237 | 0.68 | MAPT (0.34) | — | |
| SCHEMBL3000246 | 0.67 | — | — | |
| SCHEMBL16593622 | 0.67 | CHRM3 (0.33) | CHRM3 | |
| SCHEMBL12500834 | 0.66 | APAF1 (0.35) | APAF1TDP2NSD2HKDC1 | |
| SCHEMBL6129224 | 0.66 | ALDH1A1 (0.32) | APAF1TDP2NSD2HKDC1 | |
| SCHEMBL6129248 | 0.66 | MAPT (0.45) | APAF1TDP2NSD2HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050000529-A1 | Method and compositions for imparting cooling effect to tobacco products | VECTOR TOBACCO INC. | 2005-01-06 | — | — | US | claimed |
| EP-1455609-A2 | METHOD AND COMPOSITIONS FOR IMPARTING COOLING EFFECT TO TOBACCO PRODUCTS | Vector Tobacco Inc. (US) | 2004-09-15 | — | — | EP | claimed |
| US-20040052828-A1 | Consumable product including consumable component and alpha-keto enamine derivatives | NESTEC S.A. (CH) | 2004-03-18 | — | — | US | claimed |
| US-6592884-B2 | Food, cosmetics, drugs; cooling skin, mouth | NESTEC S.A. (CH) | 2003-07-15 | — | — | US | claimed |
| WO-2003053176-A2 | METHOD AND COMPOSITIONS FOR IMPARTING COOLING EFFECT TO TOBACCO PRODUCTS | VECTOR TOBACCO INC. (US) | 2003-07-03 | — | — | WO | claimed |
| US-20020022039-A1 | Method of using alpha-keto enamine derivatives as ingredients and products incorporating same | NESTEC S.A. (CH) | 2002-02-21 | — | — | US | claimed |
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-7893072-B2 | Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893072-B2 | Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20050000529-A1 | Method and compositions for imparting cooling effect to tobacco products | VECTOR TOBACCO INC. | 2005-01-06 | — | — | US | disclosed |
| EP-1455609-A2 | METHOD AND COMPOSITIONS FOR IMPARTING COOLING EFFECT TO TOBACCO PRODUCTS | Vector Tobacco Inc. (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040052828-A1 | Consumable product including consumable component and alpha-keto enamine derivatives | NESTEC S.A. (CH) | 2004-03-18 | — | — | US | disclosed |
| US-6592884-B2 | Food, cosmetics, drugs; cooling skin, mouth | NESTEC S.A. (CH) | 2003-07-15 | — | — | US | disclosed |
| WO-2003053176-A2 | METHOD AND COMPOSITIONS FOR IMPARTING COOLING EFFECT TO TOBACCO PRODUCTS | VECTOR TOBACCO INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| US-20020022039-A1 | Method of using alpha-keto enamine derivatives as ingredients and products incorporating same | NESTEC S.A. (CH) | 2002-02-21 | — | — | US | disclosed |
| EP-1157617-A2 | Use of alpha-keto enamine derivatives as ingredients | Société des Produits Nestlé S.A. (CH) | 2001-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052828-A1 | Consumable product including consumable component and alpha-keto enamine derivatives | PKN2, OPRD1, PKN1 | APAF1 3645/4885TDP2 2574/4885NSD2 415/4885 |
| US-20020022039-A1 | Method of using alpha-keto enamine derivatives as ingredients and products incorporating same | ECH1, KMO, PKN1 | APAF1 3243/4885TDP2 2352/4885NSD2 814/4885 |
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | TSG101, TP53, BAX | APAF1 548/4885TDP2 230/4885NSD2 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.